Eurobio Scientific finalizes the acquisition of CareDX’s transplant Lab Product division

About this update from Eurobio-scientific Sa

EUROBIO SCIENTIFIC FINALIZES THE ACQUISITION OF CAREDX's TRANSPLANT LAB PRODUCT DIVISION Paris, July 1st, 2026 ,8 AM CET Eurobio Scientific (FR0013240934, ALERS, PEA-PME eligible), a leading French group in in-vitro diagnostics for transplantation, oncology and infectious diseases, today announces that it has closed the acquisition of CareDx AB in Sweden and its fully owned subsidiaries in the United States and Australia that constitutes the Lab Products division of CareDx, Inc., a US global precision medicine company focused on transplantation. Combined with Eurobio Scientific affiliate GenDx's expertise in next-generation sequencing ("NGS") assays, software and global commercial footprint, this acquisition brings together two highly complementary portfolios in human leukocyte antigen ("HLA)" typing and transplantation diagnostics. Strategic RationaleThis acquisition enables GenDx to offer a more comprehensive portfolio across the transplantation IVD workflow, from pre-transplant HLA typing to post-transplant monitoring solutions. The combined entity will offer an expanded portfolio of molecular assays, reagents, and software, with the aim of enabling laboratories to streamline operations and improve clinical outcomes. The integration of CareDx's Lab Products division strengthens GenDx's presence in key markets, including the United States, Europe and Asia-Pacific, while enhancing its ability to serve both research and clinical laboratories. Key Highlights Transaction detailsEurobio Scientific has acquired CareDx's Lab Products business for a cash purchase price in the amount of €145 million ($170 million) approximately, after customary adjustments.

View stock analysis, news, and events for Eurobio-scientific Sa